Par Pharmaceutical (PRX) Tops Q2 EPS by 7c
Tweet Send to a FriendGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Revenue Growth %: +31.3%
Financial Fact:
Total operating expenses: 119.06M
Today's EPS Names:
SFL, RL, PERY, More
Revenue Growth %: +31.3%
Financial Fact:
Total operating expenses: 119.06M
Today's EPS Names:
SFL, RL, PERY, More
Trade PRX Now!
Par Pharmaceutical (NYSE: PRX) reported Q2 EPS of $0.84, $0.07 better than the analyst estimate of $0.77. Revenue for the quarter came in at $224.2 million versus the consensus estimate of $216.47 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hewlett-Packard Company (HPQ) Tops Q2 EPS by 6c as Sales Slide 10%
- Semtech Corp (SMTC) Reports In-Line Q1 EPS, Offers Q2 Guidance
- L Brands, Inc. (LTD) Tops Q1 EPS by 2c; Guides Q2, FY13 EPS
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
